Biotech Stock Boom Times Are Back

Biotech stocks are booming again.

The iShares Nasdaq Biotechnology ETF (IBB) closed at 272.63 Monday, less than one point below the year (and all-time) closing high reached on Feb. 25. The sector's steep sell off in March and April are a distant memory. Roche's (RHHBY) acquisition of InterMune (ITMN) has put some M&A oomph into biotech stocks.


IBB Chart

As you'd expect, biotech stocks are out-performing the S&P 500.


IBB Chart

The S&P Biotech ETF (XBI) is also showing a strong recovery but not as much as the IBB given the former's broader exposure to small-cap stocks.


XBI Chart

Gilead Sciences (GILD) leads the biotech big caps by a wide margin:


GILD Chart

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

More from Investing

Jim Cramer on Zillow's New Business: Buying and Selling Homes

Jim Cramer on Zillow's New Business: Buying and Selling Homes

Jim Cramer: Wabtec Deal Gives General Electric Optionality

Jim Cramer: Wabtec Deal Gives General Electric Optionality

Jim Cramer on the Markets: It's Natural to Have Some Profit Taking

Jim Cramer on the Markets: It's Natural to Have Some Profit Taking

Video: Jim Cramer on the Markets, Oil, General Electric, Zillow and Micron

Video: Jim Cramer on the Markets, Oil, General Electric, Zillow and Micron

Kroger CEO: Even in the Age of Amazon, Physical Stores Will Still Be Important

Kroger CEO: Even in the Age of Amazon, Physical Stores Will Still Be Important